Shockwave Medical (SWAV) Tops Q2 EPS by 6c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street slides as AI cash burn worries spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Six killed in cyclone off India's eastern coast
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Qualcomm shares fall on Intel warning and legal concerns
- Sandisk announces 8-for-1 forward stock split effective November 2026
- Reddit, Inc. (RDDT) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Shockwave Medical Reports Second Quarter 2020 Financial Results
August 11, 2020 4:06 PM EDTSANTA CLARA, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2020.
Recent Highlights
Recognized revenue of $10.3 million for the second quarter of 2020, representing a 3% increase over the second quarter of 2019Completed enrolment in the CAD III pivotal study of IVL for coronary use in the United StatesCompleted enrolment in... More


